About the Company
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SELB News
Selecta Biosciences Narrows R&D Focus On Gout Candidate
Selecta Biosciences Inc (NASDAQ: SELB) provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed ...
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?
We feel now is a pretty good time to analyse Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) business as it appears the company may be on the cusp of a considerable accomplishment. Cellectar ...
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies ...
Earl Sands's Net Worth
Earl Sands does not have any significant net worth to report based on the numbers we have. This is based on reported shares in SELECTA BIOSCIENCES INC.
Cartesian Therapeutics Inc (RNAC)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Pulse Biosciences, Inc. (PLSE)
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript March 28, 2024 Pulse Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
Neurocrine Biosciences Inc NBIX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Forte Biosciences Inc.
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase ...
Cellectar Biosciences Inc CLRB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cartesian Therapeutics Inc (RNAC)
WATERTOWN - Selecta Biosciences (NASDAQ:SELB), a biotech company based in ... Investors following Cartesian Therapeutics, Inc. (NASDAQ:RNAC) might be interested to learn that Timothy A. Springer, a ...
Loading the latest forecasts...